Alx Oncology Holdings ALXO
NASDAQ ALXO
$1.22 -0.08 (-6.15%)
At close: Oct 2, 2026 · 4:00 PM EDT

Alx Oncology Holdings (ALXO) Gains from Sales and Divestitures (2024 - 2026)

Updated

Alx Oncology Holdings' Gains from Sales and Divestitures was -$200,000 in Q2 2026.

Analysis

Alx Oncology Holdings (ALXO) Gains from Sales and Divestitures (2024 - 2026) Analysis & Trends

For FY2024, Gains from Sales and Divestitures at Alx Oncology Holdings came in at -$10,000.

  • The Q2 2026 figure marks the highest quarterly Gains from Sales and Divestitures since Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Alx Oncology Holdings 168.62 Mn 168.62 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -200,000.00
Mar 31, 2024 -10,000.00
API Access

Alx Oncology Holdings Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ALXO&period=max&api_key=YOUR_API_KEY